Should I buy or sell Kinnate Biopharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares. View KNTE analyst ratings or view top-rated stocks .

What is Kinnate Biopharma's stock price target for 2024?

5 brokerages have issued twelve-month target prices for Kinnate Biopharma's shares. Their KNTE share price targets range from $4.00 to $26.00. On average, they expect the company's stock price to reach $14.60 in the next year. This suggests a possible upside of 548.9% from the stock's current price. View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts .

How have KNTE shares performed in 2023?

Kinnate Biopharma's stock was trading at $6.10 at the start of the year. Since then, KNTE stock has decreased by 63.1% and is now trading at $2.25. View the best growth stocks for 2023 here .

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our KNTE earnings forecast .

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, November, 9th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.04.

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Lynx1 Capital Management LP (4.24%), Acadian Asset Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.95%), Citigroup Inc. (0.89%), Citigroup Inc. (0.89%) and Rock Springs Capital Management LP (0.86%). Insiders that own company stock include Carl L Gordon , James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams. View institutional ownership trends .

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

$2.26

-0.03 (-1.31%)

(As of 04:24 PM ET)

Compare

Today's Range: $2.16
▼
$2.29
50-Day Range: $1.07
▼
$2.50
52-Week Range: $1.04
▼
$8.17

Volume: 618,131 shs
Average Volume: 548,671 shs
Market Capitalization: $106.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.60

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 548.9% Upside
$14.60 Price Target
Short Interest: Bearish
5.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.50) to ($1.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

394th out of 943 stocks

Pharmaceutical Preparations Industry

155th out of 422 stocks

3.1

Analyst's Opinion

Consensus Rating
Kinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.60, Kinnate Biopharma has a forecasted upside of 548.9% from its current price of $2.25.
Amount of Analyst Coverage
Kinnate Biopharma has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.38% of the float of Kinnate Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Kinnate Biopharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Kinnate Biopharma does not currently pay a dividend.
Dividend Growth
Kinnate Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Kinnate Biopharma is -0.81.

1.1

News and Social Media Coverage

Search Interest
7 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
MarketBeat Follows
2 people have added Kinnate Biopharma to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.50) to ($1.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kinnate Biopharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kinnate Biopharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kinnate Biopharma has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KNTE Stock News Headlines

December 3, 2023 | americanbankingnews.com

Kinnate Biopharma Inc. (NASDAQ:KNTE) Given Average Recommendation of "Hold" by Brokerages

November 24, 2023 | finance.yahoo.com

Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 15, 2023 | msn.com

Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?

November 15, 2023 | finance.yahoo.com

OrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma Inc

November 9, 2023 | finance.yahoo.com

Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

October 4, 2023 | theglobeandmail.com

Instrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)

October 3, 2023 | finance.yahoo.com

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 20, 2023 | msn.com

Jefferies Maintains Kinnate Biopharma (KNTE) Buy Recommendation

September 19, 2023 | msn.com

Bay Area biotech company Kinnate to lay off 70% of workforce

September 19, 2023 | msn.com

Wedbush Downgrades Kinnate Biopharma (KNTE)

September 19, 2023 | msn.com

Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?

September 19, 2023 | msn.com

Piper Sandler Downgrades Kinnate Biopharma (KNTE)

September 19, 2023 | markets.businessinsider.com

Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring

September 18, 2023 | msn.com

Kinnate slashes workforce by 70%, shelves three drug programs

September 18, 2023 | finance.yahoo.com

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

August 15, 2023 | markets.businessinsider.com

Kinnate Biopharma (KNTE) Receives a Buy from H.C. Wainwright

August 8, 2023 | finance.yahoo.com

Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

July 28, 2023 | seekingalpha.com

KRBP Kiromic BioPharma, Inc.

June 11, 2023 | msn.com

Kinnate Biopharma: Trading Below Cash Value

June 8, 2023 | msn.com

HC Wainwright & Co. Reiterates Kinnate Biopharma (KNTE) Buy Recommendation

June 8, 2023 | msn.com

10 Analysts Have This to Say About Kinnate Biopharma

June 8, 2023 | msn.com

The Latest Analyst Ratings for Kinnate Biopharma

June 7, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Hold Rating on Kinnate Biopharma (KNTE)

May 30, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Hold Rating on Kinnate Biopharma (KNTE)

May 18, 2023 | markets.businessinsider.com

Kinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248

See More Headlines

Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KNTE
CUSIP: N/A
CIK: 1797768
Web: www.kinnate.com
Phone: 858-299-4699
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.60
High Stock Price Target: $26.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +537.6%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -62.31%
Return on Assets: -54.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.80
Quick Ratio: 10.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.06 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 47,113,000
Free Float: 27,467,000
Market Cap: $107.89 million
Optionable: Not Optionable
Beta: 1.34

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Nima Farzan M.B.A. (Age 47)
President, CEO & Director
Comp: $891.95k
Ms. Neha Krishnamohan (Age 36)
CFO, Principal Accounting Officer and Executive VP of Corporate Development
Comp: $548.95k
Mr. Mark A. Meltz (Age 49)
COO, General Counsel, Treasurer & Secretary
Comp: $671.86k
Dr. Richard Thomas Williams MBBS (Age 54)
Ph.D., Chief Medical Officer
Dr. Robert Kania Ph.D.
Senior Vice President of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares.
View KNTE analyst ratings or view top-rated stocks.
What is Kinnate Biopharma's stock price target for 2024?: 5 brokerages have issued twelve-month target prices for Kinnate Biopharma's shares. Their KNTE share price targets range from $4.00 to $26.00. On average, they expect the company's stock price to reach $14.60 in the next year. This suggests a possible upside of 548.9% from the stock's current price.
View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts.
How have KNTE shares performed in 2023?: Kinnate Biopharma's stock was trading at $6.10 at the start of the year. Since then, KNTE stock has decreased by 63.1% and is now trading at $2.25.
View the best growth stocks for 2023 here.
When is Kinnate Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our KNTE earnings forecast.

How were Kinnate Biopharma's earnings last quarter?: Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, November, 9th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.04.
When did Kinnate Biopharma IPO?: (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.
Who are Kinnate Biopharma's major shareholders?: Kinnate Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Lynx1 Capital Management LP (4.24%), Acadian Asset Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.95%), Citigroup Inc. (0.89%), Citigroup Inc. (0.89%) and Rock Springs Capital Management LP (0.86%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends.
How do I buy shares of Kinnate Biopharma?: Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KNTE) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Kinnate Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kinnate Biopharma Stock (NASDAQ:KNTE)

KNTE Stock Price History

KNTE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KNTE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™